The first case of acquisition in 2015! Shire's $5.2 billion acquisition of NPS

Source: Biovalley, January 12, 2015, when analysts in the biomedical industry looked back on the booming merger wave in the pharmaceutical field in 2014, shire company has quietly reached a purchase agreement with NPS pharmaceutical, a famous developer of rare disease drugs This is also the first medical acquisition case to be seen in the media in 2015, suggesting that the capital operation of the biomedical industry will still be a theme in 2015 According to the news, shire will acquire NPs at a 51% premium to the share price of NPs, i.e US $46 per share, with a total agreement of US $5.2 billion Through this merger, shire will take NPs's R & D Department of rare disease drugs into its pocket, which is also an important part of shire's future development strategy Looking back to 2014, Aberdeen and shire reached a merger agreement worth tens of billions of dollars However, with the tightening of the Obama administration's Overseas Merger Policy for biomedical enterprises, the merger case was stillborn Prior to that, as a biomedical company in Ireland, the low tax rate of shire made it a hot spot in the eyes of many biomedical giants However, with the counterattack of the U.S government, the acquisition value of shire also shrank But that doesn't mean shire will do nothing in the new year In fact, Flemming ornskov, the new CEO of shire, has been known for promoting the acquisition and merger business of shire On the other hand, Pfizer, which was very active in the acquisition market in 2014, also sent a signal that it was unwilling to be lonely Pfizer has been looking for other potential acquisitions since its failed attempt to buy AstraZeneca for $117 billion in 2014 According to some sources, Pfizer has listed Aberdeen, GlaxoSmithKline, Bristol Myers Squibb and Actavis as potential merger targets If the news is true, Pfizer will set off a huge wave in the biomedical market in 2015.